Human Immunodeficiency Virus (HIV)depistageVIHNCT07418385
Voluntary HIV Screening in the General Population in France
An observational study of Human Immunodeficiency Virus (HIV), run by Université de Reims Champagne-Ardenne at 1 site in France.
Trial summary
Since 2020, an increase in positive screenings for sexually transmitted infections, including HIV, has been observed. Voluntary early screening plays an important role in the national strategy for HIV care in France. There are currently several methods that allow patients to undergo voluntary screening. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Human Immunodeficiency Virus (HIV)
- What is being tested?
- data collections
- How many people
- 1,000 participants
- Where
- 1 siteFrance
- Study dates
- 7 Oct 2025to 1 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subjects aged 18 years or older, whether or not they have previously undergone voluntary HIV testing, residing in France, and agreeing to participate in the study.
Who may be able to join
- 18 years of age or older
- Male or female
- Regardless of sexual orientation
- Whether or not they have previously undergone voluntary HIV testing
- Agreeing to participate in the study.
Who cannot join
- Minors
- Refusing to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Ufr Medecine Urca
Reims, 51100
Coralie Barbe, 326913665 ext. +33, coralie.barbe1@univ-reims.fr
About this study
Since 2020, an increase in positive screenings for sexually transmitted infections, including HIV, has been observed.
Voluntary early screening plays an important role in the national strategy for HIV care in France. There are currently several methods that allow patients to undergo voluntary screening.
Read the detailed description
Objectives
The main objective is to describe the voluntary HIV screening methods used by the general population in France.
- Conditions
- Human Immunodeficiency Virus (HIV)
- Being tested
- data collections
- Keywords
- HIV, voluntary screening
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
data collectionsOther
data collections
What is being measured
The primary outcome is the main question the study is designed to answer.
The method(s) used for undergoing voluntary HIV testing questionnaire
The method(s) used for undergoing voluntary HIV testing: medical prescription, Center for Free Information, Testing, and Diagnosis, medical laboratory, rapid diagnostic test (RDT), or self-test
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start7 Oct 2025
- Primary completion7 Apr 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human Immunodeficiency Virus (HIV)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université de Reims Champagne-Ardenne
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07418385
- Sponsor's protocol ID
- 2025_RIPH_08_DEPISTAGEVIH
- Acronym
- depistageVIH
- Status last verified
- Feb 2026
- First submitted
- 11 Feb 2026
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Voluntary HIV Screening in the General Population in France
- ClinicalTrials.gov ID
- NCT07418385
- Acronym / sponsor ID
- depistageVIH / 2025_RIPH_08_DEPISTAGEVIH
- Conditions
- Human Immunodeficiency Virus (HIV)
- Keywords
- HIV, voluntary screening
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Université de Reims Champagne-ArdenneUniversity, hospital or other
- Study start
- 7 Oct 2025 (actual)
- Primary completion
- 7 Apr 2026 (estimated)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Since 2020, an increase in positive screenings for sexually transmitted infections, including HIV, has been observed.
Voluntary early screening plays an important role in the national strategy for HIV care in France. There are currently several methods that allow patients to undergo voluntary screening.
Detailed description
Objectives
The main objective is to describe the voluntary HIV screening methods used by the general population in France.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects aged 18 years or older, whether or not they have previously undergone voluntary HIV testing, residing in France, and agreeing to participate in the study.
Key inclusion criteria (5 listed)
- 18 years of age or older
- Male or female
- Regardless of sexual orientation
- Whether or not they have previously undergone voluntary HIV testing
- Agreeing to participate in the study.
Key exclusion criteria (2 listed)
- Minors
- Refusing to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| data collectionsdata collections | Other | – |
Primary outcome
The method(s) used for undergoing voluntary HIV testing questionnaire
Time frame: Day 0
The method(s) used for undergoing voluntary HIV testing: medical prescription, Center for Free Information, Testing, and Diagnosis, medical laboratory, rapid diagnostic test (RDT), or self-test
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Human Immunodeficiency Virus (HIV)
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Human Immunodeficiency Virus (HIV), run by Université de Reims Champagne-Ardenne at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gestonnairedu CURRS (0326918822 ext. +33, currs@univ-reims.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The method(s) used for undergoing voluntary HIV testing questionnaire (time frame: Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.